Though previous studies have combined different BCSCs biomarkers for assessing prognosis in different types of breast cancer, such as three-negative, HER2-positive and metastatic breast cancer [56–59], no BCSC-associated biomarkers have been combined to form a model for evaluating the relapse risk of early-stage breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.